Kardigan Completes KATALYST-AV Enrollment; Pushes AVC Endpoint to Week 48, Topline Now 2H 2027
KARD sits 30% above its 52-week low of $12.23.
Summary
Kardigan finished enrolling 156 patients in the Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis, but amended the protocol so the primary valve-calcium endpoint is assessed at Week 48, pushing topline data to the second half of 2027.
Key Events · Product Development and Regulatory · KARD
-
KATALYST-AV Enrollment Complete
Kardigan enrolled 156 patients in the Phase 2b trial of ataciguat in aortic stenosis; baseline data cover the first 139 intent-to-treat participants.
-
Primary Endpoint Moved to Week 48
The aortic valve calcium endpoint will now be assessed at Week 48 alongside aortic valve area and cardiac structure/function measures. The amendment was made under blinded conditions and was not prompted by any safety finding.
-
Topline Data Pushed to 2H 2027
Week 48 topline is now expected in the second half of 2027, with an internal Week 24 interim analysis and a Phase 3 development plan update in the first half of 2027.
-
Real-World Data Inform Phase 3 Design
In roughly 45,000 people with mild-to-moderate AS, baseline aortic valve area was the strongest predictor of progression and about 27% progressed rapidly (AVA decline of at least 0.1 cm²/year); baseline AVC did not distinguish rapid from normal progressors.
Analysis · KARD · Life Sciences
Enrollment of 156 patients is the milestone the market was waiting for, but the more consequential news is the protocol amendment: the primary aortic valve calcium endpoint now reads out at Week 48 instead of an earlier point, and topline data slipped to the second half of 2027. Management says the change was made blinded and was not driven by any safety finding — the baseline AVC spread (320 to 1,983 Agatston units) simply means calcium accrues at each patient's own rate, so more time is needed to separate ataciguat from placebo. That pushes the key binary readout for the lead program roughly a year out and adds a Week 24 internal interim analysis plus a Phase 3 design update in the first half of 2027. The 45,000-patient real-world dataset is the constructive counterweight: it identifies rapid progressors and supports the patient-selection and endpoint design for the Phase 3 registrational trial.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KARD was trading at $15.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $12.23 to $27.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.